Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma

Texto completo
Autor(es):
Mostrar menos -
de Almeida, Luciana Y. [1] ; Mariano, Flavia S. [1] ; Bastos, Debora C. [1] ; Cavassani, Karen A. [2] ; Raphelson, Janna [2] ; Mariano, Vania S. [3] ; Agostini, Michelle [4] ; Moreira, Fernanda S. [1] ; Coletta, Ricardo D. [1] ; Mattos-Graner, Renata O. [1] ; Graner, Edgard [1]
Número total de Autores: 11
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, UNICAMP, Sch Dent Piracicaba, Dept Oral Diag, Av Limeira 901, CP 52, BR-13414903 Piracicaba, SP - Brazil
[2] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Urol Oncol Program, Urooncol Res Labs, Los Angeles, CA 90048 - USA
[3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Basic & Appl Immunol, Sao Paulo, SP - Brazil
[4] Univ Fed Rio de Janeiro, Sch Dent, Dept Oral Diag & Pathol, Rio De Janeiro - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: Cancer Chemotherapy and Pharmacology; v. 85, n. 2 DEC 2019.
Citações Web of Science: 0
Resumo

Purpose Fatty acid synthase (FASN), the multifunctional enzyme responsible for endogenous fatty acid synthesis, is highly expressed and associated with poor prognosis in several human cancers, including melanoma. Our group has previously shown that pharmacological inhibition of FASN with orlistat decreases proliferation, promotes apoptosis, and reduces the metastatic spread of B16-F10 cells in experimental models of melanoma. While most of the orlistat antitumor properties seem to be closely related to direct effects on malignant cells, its impact on the host immune system is still unknown. Methods The effects of orlistat on the phenotype and activation status of infiltrating leukocytes in primary tumors and metastatic lymph nodes were assessed using a model of spontaneous melanoma metastasis (B16-F10 cells/C57BL/6 mice). Cells from the primary tumors and lymph nodes were mechanically dissociated and immune cells phenotyped by flow cytometry. The expression of IL-12p35, IL-12p40, and inducible nitric oxide synthase (iNOS) was analyzed by qRT-PCR and production of nitrite (NO2-) evaluated in serum samples with the Griess method. Results Orlistat-treated mice exhibited a 25% reduction in the number of mediastinal lymph node metastases (mean 3.96 +/- 0.78, 95% CI 3.63-4.28) compared to the controls (mean 5.7 +/- 1.72; 95% CI 5.01-6.43). The drug elicited an antitumor immune response against experimental melanomas by increasing maturation of intratumoral dendritic cells (DC), stimulating the expression of cytotoxicity markers in CD8 T lymphocytes and natural killer (NK) cells, as well as reducing regulatory T cells (Tregs). Moreover, the orlistat-treatment increased serum levels of nitric oxide (NO) concentrations. Conclusion Taken together, these findings suggest that orlistat supports an antitumor response against experimental melanomas by increasing CD80/CD81-positive and IL-12-positive DC populations, granzyme b/NKG2D-positive NK populations, and perforin/granzyme b-positive CD8 T lymphocytes as well as reducing Tregs counts within experimental melanomas. (AU)

Processo FAPESP: 10/52670-1 - Efeitos da inibicao endogena de acidos graxos em melanomas experimentais sobre a resposta imune antitumoral.
Beneficiário:Flávia Sammartino Mariano Rodrigues
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 08/57471-7 - Análise da participação da produção endógena de ácidos graxos nos mecanismos de apoptose, metástase e vasculogênese em melanoma
Beneficiário:Edgard Graner
Modalidade de apoio: Auxílio à Pesquisa - Temático
Processo FAPESP: 12/25160-8 - Estudo dos efeitos da terapia combinada orlistat / cisplatina / 5-fluorouracil sobre o processo metastático em modelo ortotópico de carcinoma espinocelular de língua.
Beneficiário:Luciana Yamamoto de Almeida
Modalidade de apoio: Bolsas no Brasil - Doutorado